

Lecia V Sequist

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6685715/lecia-v-sequist-publications-by-citations.pdf>
Version: 2024-04-02

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232 papers	38,997 citations	78 h-index	197 g-index
253 ext. papers	45,575 ext. citations	9.3 avg, IF	6.9 L-index

#	Paper	IF	Citations
232	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
231	Isolation of rare circulating tumour cells in cancer patients by microchip technology. <i>Nature</i> , 2007 , 450, 1235-9	50.4	2834
230	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. <i>Science Translational Medicine</i> , 2011 , 3, 75ra26	17.5	2425
229	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3327-34	2.2	2262
228	Detection of mutations in EGFR in circulating lung-cancer cells. <i>New England Journal of Medicine</i> , 2008 , 359, 366-77	59.2	1399
227	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2015 , 16, 141-51	21.7	1081
226	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1998-2006	27.4	1042
225	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. <i>Science Translational Medicine</i> , 2012 , 4, 120ra17	17.5	948
224	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2004-12	2.2	859
223	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2010 , 17, 77-88	24.3	816
222	Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. <i>Science Translational Medicine</i> , 2013 , 5, 179ra47	17.5	777
221	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2442-9	2.2	725
220	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016 , 22, 4585-93	12.9	655
219	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1118-1133	24.4	648
218	Acquired resistance to TKIs in solid tumours: learning from lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 473-81	19.4	591
217	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology, The</i> , 2015 , 16, 830-8	21.7	551
216	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. <i>Nature Medicine</i> , 2016 , 22, 262-9	50.5	533

215	Rociletinib in EGFR-mutated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1700-9	59.2	524
214	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 587-95	2.2	515
213	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. <i>Science</i> , 2014 , 346, 1480-6	33.3	507
212	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2006 , 12, 3908-14	12.9	479
211	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology, The</i> , 2015 , 16, e165-72	21.7	477
210	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science</i> , 2015 , 349, 1351-6	33.3	476
209	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016 , 7, 11815	17.4	409
208	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1675-1684	2.2	381
207	Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015 , 5, 713-22	24.4	368
206	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2127-33	11.5	366
205	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
204	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015 , 6, 6377	17.4	358
203	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. <i>Clinical Cancer Research</i> , 2015 , 21, 3924-33	12.9	344
202	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3076-83	2.2	343
201	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3307-15	2.2	343
200	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. <i>EMBO Molecular Medicine</i> , 2010 , 2, 146-58	12	333
199	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1248-1268	8.9	331
198	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 539-48	21.7	331

197	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <i>Clinical Cancer Research</i> , 2009 , 15, 5267-73	12.9	328
196	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 216ra177	17.5	313
195	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4953-60	2.2	296
194	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016 , 22, 1103-10	12.9	282
193	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 157-165	2.2	268
192	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 380-90	8.9	240
191	BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. <i>Cancer Discovery</i> , 2011 , 1, 352-65	24.4	224
190	Landscape of Acquired Resistance to Osimertinib in -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired Fusion. <i>Cancer Discovery</i> , 2018 , 8, 1529-1539	24.4	205
189	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1690-700	8.9	203
188	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. <i>Neuro-Oncology</i> , 2010 , 12, 1193-9	1	201
187	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2667-74	2.2	200
186	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3068-77	12.9	192
185	Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. <i>Journal of Molecular Diagnostics</i> , 2007 , 9, 320-6	5.1	169
184	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019 , 37, 278-285	2.2	165
183	Brain tumor cells in circulation are enriched for mesenchymal gene expression. <i>Cancer Discovery</i> , 2014 , 4, 1299-309	24.4	159
182	Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. <i>Nature Communications</i> , 2018 , 9, 175	17.4	158
181	The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 281-3	8.9	158
180	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020 , 21, 373-386	21.7	148

179	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020 , 580, 245-251	50.4	147
178	FGFR1 amplification in squamous cell carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1775-1780	8.9	147
177	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016 , 22, 2386-95	12.9	138
176	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. <i>Oncologist</i> , 2007 , 12, 90-8	5.7	138
175	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 124-129	8.9	137
174	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <i>Clinical Cancer Research</i> , 2008 , 14, 7060-7	12.9	135
173	EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. <i>Annual Review of Medicine</i> , 2008 , 59, 429-42	17.4	120
172	Lung cancer. <i>Lancet, The</i> , 2021 , 398, 535-554	40	115
171	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2012 , 13, 391-5	4.9	114
170	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. <i>Oncologist</i> , 2013 , 18, 1214-20	5.7	108
169	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. <i>Cancer Discovery</i> , 2011 , 1, 608-25	24.4	108
168	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 1123-1128	11.5	104
167	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. <i>Journal of Thoracic Oncology</i> , 2015 , 10, S1-63	8.9	102
166	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018 , 24, 1038-1047	12.9	100
165	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1242-1245	8.9	98
164	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018 , 8, 600-615	24.4	96
163	Circulating tumour cells-monitoring treatment response in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 401-12	19.4	96
162	Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. <i>Scientific Reports</i> , 2017 , 7, 10936	4.9	94

161	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 97-104	2.2	83
160	RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 541-549	8.9	83
159	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2467-2472	11.5	82
158	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. <i>Cell Reports</i> , 2017 , 21, 3298-3309	10.6	82
157	Isolation and molecular characterization of circulating melanoma cells. <i>Cell Reports</i> , 2014 , 7, 645-53	10.6	81
156	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. <i>Oncogene</i> , 2019 , 38, 6399-6413	9.2	79
155	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019 , 125, 892-901	6.4	78
154	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018 , 8, 288-303	24.4	76
153	Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2027-2032	8.9	75
152	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019 , 9, 1372-1387	24.4	74
151	The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. <i>Annals of Thoracic Surgery</i> , 2013 , 96, 962-8	2.7	69
150	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 4403s-4408s	12.9	68
149	Update to Rociletinib Data with the RECIST Confirmed Response Rate. <i>New England Journal of Medicine</i> , 2016 , 374, 2296-7	59.2	65
148	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e83-5	8.9	64
147	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
146	Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. <i>Oncologist</i> , 2011 , 16, 319-26	5.7	61
145	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2022-2026	8.9	60
144	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	60

143	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017 , 77, 2018-2028	10.1	59
142	Expression of Hglobin by cancer cells promotes cell survival during blood-borne dissemination. <i>Nature Communications</i> , 2017 , 8, 14344	17.4	58
141	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2018 , 8, 1286-1299	24.4	58
140	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1150-1160	10.2	57
139	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. <i>Neuro-Oncology</i> , 2015 , 17, 296-302	1	57
138	First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8010-8010	2.2	57
137	Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. <i>Biomaterials</i> , 2015 , 65, 93-102	15.6	55
136	Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1601-7	8.9	54
135	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Oncologist</i> , 2007 , 12, 325-30	5.7	54
134	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500	2.2	53
133	Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. <i>Journal of Clinical Oncology</i> , 2020 , JCO1903123	2.2	51
132	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. <i>Clinical Cancer Research</i> , 2018 , 24, 197-208	12.9	50
131	Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8029-8029	2.2	49
130	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in -Mutant Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2018 , 8, 1598-1613	24.4	48
129	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48
128	Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. <i>Oncologist</i> , 2011 , 16, 886-95	5.7	47
127	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 135-140	8.9	46
126	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 576-584	8.9	45

125	Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?. <i>Medicine (United States)</i> , 2019 , 98, e13963	1.8	41
124	Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. <i>JAMA Oncology</i> , 2016 , 2, 541-3	13.4	41
123	Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. <i>Clinical Cancer Research</i> , 2008 , 14, 6867-76	12.9	40
122	MET amplification (amp) as a resistance mechanism to osimertinib.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9020-9020	2.2	39
121	Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3330-6	2.2	38
120	Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. <i>Nature Communications</i> , 2017 , 8, 1733	17.4	37
119	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018 , 101, 201-209	7.5	36
118	Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, S1029-39; quiz S1041-2	8.9	36
117	ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9513-9513	2.2	36
116	Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. <i>Cancer Journal (Sudbury, Mass)</i> , 2015 , 21, 371-7	2.2	34
115	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8112-8112	2.2	33
114	A bright future for KRAS inhibitors.. <i>Nature Cancer</i> , 2020 , 1, 25-27	15.4	33
113	Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1855-8	8.9	32
112	A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8019-8019	2.2	32
111	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016 , 21, 964-73	5.7	31
110	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018 , 24, 6548-6555	12.9	31
109	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. <i>Cell Reports</i> , 2019 , 27, 3422-3432.e4	10.6	30
108	Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8030-8030	2.2	30

107	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
106	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. <i>Academic Radiology</i> , 2016 , 23, 329-36	4.3	28
105	Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e204-e206	8.9	28
104	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 561-572	35.1	26
103	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9044-9044	2.2	26
102	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 162-168	8.9	26
101	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7514-7514	2.2	25
100	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8001-8001	2.2	25
99	Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review. <i>JAMA Oncology</i> , 2016 , 2, 948-54	13.4	25
98	Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?. <i>Cancer Imaging</i> , 2019 , 19, 36	5.6	24
97	Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. <i>Clinical Cancer Research</i> , 2005 , 11, 5668-70	12.9	24
96	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7543-7543	2.2	24
95	Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8034-8034	2.2	24
94	Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 189-94	2.2	23
93	Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9001-9001	2.2	22
92	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8051-8051	2.2	20
91	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. <i>Cancer Research</i> , 2019 , 79, 3776-3788	10.1	19
90	First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2008 , 3, S143-5	8.9	19

89	Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8031-8031	2.2	19
88	Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7547-7547	2.2	18
87	Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, e187-e197	7.1	17
86	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8013-8013	2.2	17
85	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1588-1594	8.9	16
84	Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1389-96	8.9	16
83	First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2524-2524	2.2	16
82	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. <i>Cancer Cell</i> , 2021 , 39, 1531-1547.e10	24.3	16
81	Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 153-159.e3	4.9	16
80	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1095-1102	5.7	16
79	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. <i>Technology in Cancer Research and Treatment</i> , 2016 , 15, 234-42	2.7	15
78	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 792-800	8.9	15
77	Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7509-7509	2.2	15
76	Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8012-8012	2.2	15
75	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019 , 133, 10-19	5.9	14
74	Targeting Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. <i>Cancer Discovery</i> , 2021 , 11, 2145-2157	24.4	13
73	Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e135-e139	8.9	13
72	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	13

71	Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. <i>Oncologist</i> , 2011 , 16, 1299-306	5.7	12
70	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500	2.2	12
69	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 850-859	8.9	12
68	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 117, 44-49	5.9	11
67	Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2280-2	2.2	11
66	Imaging Features and Metastatic Patterns of Advanced -Rearranged Non-Small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2020 , 214, 766-774	5.4	11
65	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2899-2909	12.9	11
64	Clinical Utility of Rapid Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	11
63	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1522-8	8.9	10
62	A new BATTLE in the evolving war on cancer. <i>Cancer Discovery</i> , 2011 , 1, 14-6	24.4	10
61	The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7010-7010	2.2	10
60	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8015-8015	2.2	10
59	Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9072-9072	2.2	10
58	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9586-9586	2.2	10
57	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e226-e228	8.9	10
56	Diffuse Lung Metastases in -Mutant Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	9
55	Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). <i>Cancer</i> , 2018 , 124, 2407-2414	6.4	9
54	Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e95-e97	8.9	9

53	Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7525-7525	2.2	8
52	24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9026-9026	2.2	8
51	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9094-9094	2.2	8
50	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. <i>Clinical Lung Cancer</i> , 2021 , 22, 201-209	4.9	8
49	Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018 , 22, 542-548	1.1	8
48	Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1570-1576	5.7	7
47	Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer. <i>Palliative and Supportive Care</i> , 2013 , 11, 223-9	2.5	7
46	End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. <i>Journal of Palliative Medicine</i> , 2016 , 19, 1316-1319	2.2	6
45	Treatment of advanced non-small cell lung cancer in the elderly. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 289-97	3.9	6
44	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7524-7524	2.2	6
43	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8053-8053	2.2	6
42	Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. <i>Oncologist</i> , 2020 , 25, 431-437	5.7	6
41	A Th1/IFN γ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1725-1735	12.9	6
40	Genotyping lung cancer is an investment in the future. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3576-7	2.2	5
39	Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 1426-35	59.2	5
38	Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2021 , 216, 318-329 [†]	5.4	5
37	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. <i>Oncologist</i> , 2020 , 25, 78-86	5.7	4
36	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018 , 19, e655-e665	4.9	4

35	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	4
34	Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7556-7556	2.2	4
33	Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9045-9045	2.2	4
32	Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. <i>Cancer Research</i> , 2020 , 80, 5121-5133	10.1	4
31	APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer		4
30	Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8031-8031	2.2	3
29	Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. <i>Clinical Lung Cancer</i> , 2021 , 22, 23-31	4.9	3
28	Transformation from NSCLC to SCLC: when did it happen? - AuthorsQepley. <i>Lancet Oncology</i> , 2015 , 16, e309-10	21.7	2
27	TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study 2014 , 2, O12		2
26	Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung. <i>New England Journal of Medicine</i> , 2008 , 359, 405-14	59.2	2
25	A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naïve patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8088-8088	2.2	2
24	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9000-9000	2.2	2
23	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9110-TPS9110	2.2	2
22	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9574-9574	2.2	2
21	Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an Tyrosine Kinase Inhibitor.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-13	3.6	2
20	The Role of Liquid Biopsies in Lung Cancer Screening. <i>Seminars in Roentgenology</i> , 2017 , 52, 185-187	0.8	1
19	The anticipated next season of EGFR inhibitors. <i>Oncologist</i> , 2015 , 20, 335-6	5.7	1
18	Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?. <i>Oncologist</i> , 2015 , 20, 1230-2	5.7	1

17	Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1170-3	8.9	1
16	LTK fusions: A new target emerges in non-small cell lung cancer.. <i>Cancer Cell</i> , 2022 , 40, 23-25	24.3	1
15	Rociletinib-associated cataracts in EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9042-9042	2.2	1
14	The challenges of repeat biopsies at acquired resistance to EGFR TKIs.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20571-e20571	2.2	1
13	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8573-8573	2.2	1
12	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. <i>Translational Lung Cancer Research</i> , 2013 , 2, 411-4	4.4	1
11	Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 126-126	2.2	1
10	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , 2018 , 6, 45-58	2.7	1
9	Biology of Lung Cancer 2016 , 912-926.e6		0
8	Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic.. <i>JAMA Network Open</i> , 2022 , 5, e224840	10.4	0
7	Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer 2019 , 115-131		
6	Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20508-e20508	2.2	
5	End of life (EOL) care in patients with metastatic lung cancer harboring EGFR-mutations.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20508-e20508	2.2	
4	Characteristics of NSCLCs harboring NRAS mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7532-7532	2.2	
3	A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7546-7546	2.2	
2	Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8085-8085	2.2	
1	Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of -Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100128	1.4	